Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

06.11.2018 | short review | Ausgabe 4/2018

memo - Magazine of European Medical Oncology 4/2018

Lutetium-PSMA therapy—a new therapeutic option in metastatic castration-resistant prostate cancer?

memo - Magazine of European Medical Oncology > Ausgabe 4/2018
MD, FEBU Michael Ladurner, MD Univ.-Prof. Wolfgang Horninger, MD, FEBU Assoc. Prof. Jasmin Bektic


Although localized prostate cancer (PC) is a curable disease, a significant proportion of patients progress from advanced PC to metastatic castration-resistant prostate cancer (mCRPC). Several new treatments for mCRPC were approved including new hormonal therapies, chemotherapies, and radium-223. For patients with disease progression after the standard therapies, lutetium-prostate-specific membrane antigen (Lu-PSMA) therapy could be an option.
The aim of this short review is to give an overview of the available evidence of the efficacy and toxicity of Lu-PSMA therapy. To date, one prospective phase II trial and several small retrospective studies have been published including almost 400 patients. Primary endpoint of all available trials was a decline in PSA of >50%, which was achieved in 30–70% of men treated with Lu-PSMA therapy. A PSA decline was observed in 70–91% of cases. Overall survival was reported only in small retrospective subgroups, and no prospective data are available. Progressive disease was observed in 11–32% of patients after Lu-PSMA treatment.
Lu-PSMA treatment seems to be well tolerated and safe. One common treatment-related grade 1 adverse event is dry mouth in up to 87% of men after radioligand therapy (RLT). Therefore, in the vast majority no treatment is needed. Hematologic toxicity such as thrombocytopenia caused serious grade 3–4 adverse events in 27% of patients in the prospective trial. No immediate adverse events after radioligand infusion and no treatment-related deaths were reported.
According to preliminary data, Lu-PSMA therapy seems to be well tolerated and safe for progressive end-stage mCRPC patients. Further prospective trials are needed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2018

memo - Magazine of European Medical Oncology 4/2018 Zur Ausgabe